Table 3.
Multi-factor regression analysis
| Clinical factors | Hazard ratio(95% CI) | P value |
|---|---|---|
| PFS | ||
| Age | 1.209 (0.530–2.758) | 0.652 |
| Granulocyte / Lymphocyte ratio | 7.485 (1.571–35.661) | 0.012 |
| Group ( nimotuzumab group vs control group) | 1.448 (0.435–4.820) | 0.546 |
| LRFS | ||
| Age | 0.140 (0.005–3.938) | 0.248 |
| Granulocyte / Lymphocyte ratio | 0.469 (0.003–71.627) | 0.768 |
| Group ( nimotuzumab group vs control group) | 21.307 (0.231–1969.162) | 0.185 |
| DMFS | ||
| Age | 1.624 (0.629–4.188) | 0.316 |
| Granulocyte / Lymphocyte ratio | 17.540 (2.019–152.340) | 0.009 |
| Group ( nimotuzumab group vs control group) | 1.520 (0.425–5.432) | 0.520 |
| OS | ||
| Age | 4.798 (0.364–63.245) | 0.233 |
| Granulocyte / Lymphocyte ratio | 693654.379 (0.000–1.729×10168) | 0.944 |
| Group ( nimotuzumab group vs control group) | 15.122 (0.346–661.641) | 0.159 |